| Deler fremragende | 86,259,358 shares |
| Insideraktier | 5.328.968 shares |
| Insider ejerskab | 6,18 % |
| Total Insiders | 41 |
Insider-stemningsscore
Insider Sentiment Score viser, at virksomhederne bliver købt af virksomheders insidere.
Det er resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af insider-akkumulering. Scoringsmodellen bruger en kombination af nettoantallet af insidere, der har købt de foregående 90 dage, det samlede antal aktier købt som en procentdel af float og det samlede antal aktier ejet af insidere. Tallet går fra 0 til 100, hvor højere tal indikerer et højere niveau af akkumulering for sine jævnaldrende, og 50 er gennemsnittet.
Opdateringsfrekvens: Dagligt
Se Insiders Top Picks, som giver en liste over virksomheder med den højeste insider-akkumulering.
Officers sentiment score
Officer Sentiment Score finder virksomheder, der bliver købt af Corporate Officers.
Per definition er Corporate Officers Corporate Insiders, men i modsætning til nogle af de andre Insiders (10 % aktionærer og bestyrelsesmedlemmer), arbejder officerer for virksomheden på daglig basis, og de bruger deres egne penge, når de handler . (10 % aktionærer og bestyrelsesmedlemmer er ofte fondsforvaltere, der administrerer andres penge.) Som sådan er insiderhandler foretaget af embedsmænd meget mere betydningsfulde og bør behandles passende.
Ligesom Insider Sentiment Score er Officer Sentiment Score resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af officerakkumulering.
Opdateringsfrekvens: Dagligt
Se Insiders Top Picks, som giver en liste over virksomheder med højeste insider-stemning.
Nøgle Insider Metrics
Dette kort viser, hvordan virksomheden rangerer langs forskellige insider-metrics. Percentilrangen viser, hvordan denne virksomhed sammenligner sig med andre virksomheder på de amerikanske markeder. Højere placeringer er tegn på bedre situationer.
For eksempel er det generelt accepteret, at insider-køb er en positiv indikator, så virksomheder med flere insider-køb vil rangere højere end virksomheder med mindre insider-køb (eller endda insider-salg).
Insiderhandelsdiagram
Spyre Therapeutics, Inc. insiderhandler er vist i følgende diagram. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Generelt er det generelt ulovligt for insidere at foretage handler i deres virksomheder baseret på væsentlige, ikke-offentlige oplysninger. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4.
Insiderliste og lønsomhedsmålinger
Denne tabel viser listen over kendte insidere og genereres automatisk fra arkiveringer, der er videregivet til SEC. Ud over navnene, den seneste titel og direktør, officer eller 10 % ejerbetegnelse giver vi de seneste offentliggjorte besiddelser. Derudover giver vi, når det er muligt, den historiske handelspræstation for insideren. Den historiske handelspræstation er et vægtet gennemsnit af præstationen af faktiske købstransaktioner på det åbne marked foretaget af insideren. For mere information om, hvordan dette beregnes, se dette YouTube-webinar.
See our leaderboard of most profitable insider traders.
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| Albers Jeffrey W. Director - [D] | 27.360 | 27.360 | |
| Jonathan Alspaugh Chief Financial Officer - [O] | 165.372 | 6.615 | |
| Baker Bros. Advisors Lp Director - [D] | 3.094.590 | 123.784 | |
| Suzanne Louise Bruhn | 28.100 | ||
| Scott L Burrows Chief Financial Officer - [O] | 97.994 | 97.994 | |
| Cox Russell J. Director - [D] | 7.000 | 280 | |
| Fairmount Funds Management LLC Director - [D] | 4.018.101 | 4.018.101 | |
| George Georgiou Director - [D] | 175.861 | 7.034 | |
| Michael Thomas Henderson Director - [D] | 168.606 | 168.606 | |
| Hanley Jr. Michael Conick Chief Commercial Officer - [O] | 36.200 | 1.448 | |
| Henry Hebel | 38.200 | ||
|
Samuel D Isaly
10% Owner -
|
1.469.524 | 58.781 | |
| James Paul Kastenmayer Interim CEO & General Counsel - [O] | 8.000 | 320 |
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| V Bryan Lawlis | 28.100 | ||
|
Eli & Co Lilly
10% Owner -
|
2.068.543 | 82.742 | |
| Alison Frances Lawton | 0 | ||
|
Lilly Ventures Fund I LLC
10% Owner -
|
57.619 | 82.742 | |
| David George Lowe CEO and President, Director - [D] [O] | 5.658 | 226 | |
| Ivana Magovcevic | 28.100 | ||
| Sandesh Mahatme | 28.100 | ||
|
Ag Novartis
10% Owner -
|
2.175.314 | 87.013 | |
| Linda L Neuman Chief Medical Officer - [O] | 4.000 | 160 | |
|
Bioventures Ltd Novartis
10% Owner -
|
2.175.314 | 87.013 | |
|
Orbimed Advisors Llc
10% Owner -
|
1.469.524 | 58.781 | |
|
OrbiMed Capital GP V LLC
10% Owner -
|
1.469.524 | 58.781 | |
| Anthony Quinn President & CEO, Director - [D] [O] | 550.540 | 22.022 | |
| Madduri Ravin Rao | 25.000 |
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| Sandra Rojas-Caro | 0 | ||
| Scott W Rowlinson VP, Research - [O] | 11.204 | 448 | |
| Aaron Schuchart Chief Business Officer - [O] | 2.500 | 100 | |
|
Armen Shanafelt
Director, 10% Owner -
[D]
|
150.000 | 6.000 | |
| Leslie Sloan | 180.000 | ||
| Sheldon Sloan Chief Medical Officer - [O] | 0 | 0 | |
| Hunter C Smith | 60.000 | ||
| Marcio Souza Director - [D] | 90.000 | 3.600 | |
| Joseph E Tyler VP, Manufacturing - [O] | 42.428 | 1.697 | |
|
Torres S. Edward
10% Owner -
|
115.238 | 4.610 | |
| Cameron Turtle Chief Executive Officer, Director - [D] [O] | 612.540 | 612.540 | |
| Steven Weber VP, Controller&Princ Acctg Off - [O] | 17.652 | 706 | |
| James Wooldridge | 50.200 | ||
| Charles N II York Chief Financial Officer and VP - [O] | 34.787 | 1.391 |
Report errors via our new Insider Auditing Tool
Track Records af insiderkøb - Kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i SYRE / Spyre Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Track Records af insidersalg - Kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i SYRE / Spyre Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Transaktionshistorik
Klik på linkikonet for at se den fulde transaktionshistorik. Transaktioner, der rapporteres som en del af en automatisk handelsplan 10b5-1, vil have et X i kolonnen markeret 10b-5.
| Fil Dato |
Handle Dato |
Form | Insider | Ticker | Sikkerhedstitel | Kode | Direkte | Dyrke motion Pris |
Enhed Pris |
Enheder Ændret |
Værdi Ændret (1K) |
Tilbage Muligheder |
Tilbage Aktier |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | 2026-05-01 | 4 | Burrows Scott L | SYRE | Common Stock | D | 71,3700 | -12.500 | -892 | 97.994 | ||||
| 2026-05-01 | 2026-05-01 | 4 | Burrows Scott L | SYRE | Common Stock | D | 14,5000 | 12.500 | 181 | 110.494 | ||||
| 2026-05-01 | 2026-05-01 | 4 | Turtle Cameron | SYRE | Common Stock | D | 74,9600 | -300 | -22 | 612.540 | ||||
| 2026-05-01 | 2026-05-01 | 4 | Turtle Cameron | SYRE | Common Stock | D | 74,2300 | -1.700 | -126 | 612.840 | ||||
| 2026-05-01 | 2026-05-01 | 4 | Turtle Cameron | SYRE | Common Stock | D | 73,1400 | -3.100 | -227 | 614.540 | ||||
| 2026-05-01 | 2026-05-01 | 4 | Turtle Cameron | SYRE | Common Stock | D | 71,7600 | -1.000 | -72 | 617.640 | ||||
| 2026-05-01 | 2026-05-01 | 4 | Turtle Cameron | SYRE | Common Stock | D | 70,7700 | -3.600 | -255 | 618.640 | ||||
| 2026-05-01 | 2026-05-01 | 4 | Turtle Cameron | SYRE | Common Stock | D | 69,5400 | -5.300 | -369 | 622.240 | ||||
| 2026-05-01 | 2026-05-01 | 4 | Sloan Sheldon | SYRE | Common Stock | D | 75,3700 | -400 | -30 | 0 | ||||
| 2026-05-01 | 2026-05-01 | 4 | Sloan Sheldon | SYRE | Common Stock | D | 74,6000 | -5.059 | -377 | 400 | ||||
| 2026-05-01 | 2026-05-01 | 4 | Sloan Sheldon | SYRE | Common Stock | D | 73,7400 | -10.358 | -764 | 5.459 | ||||
| 2026-05-01 | 2026-05-01 | 4 | Sloan Sheldon | SYRE | Common Stock | D | 72,9400 | -12.777 | -932 | 15.817 | ||||
| 2026-05-01 | 2026-05-01 | 4 | Sloan Sheldon | SYRE | Common Stock | D | 71,5600 | -8.777 | -628 | 28.594 | ||||
| 2026-05-01 | 2026-05-01 | 4 | Sloan Sheldon | SYRE | Common Stock | D | 70,6100 | -19.656 | -1.388 | 37.371 | ||||
| 2026-05-01 | 2026-05-01 | 4 | Sloan Sheldon | SYRE | Common Stock | D | 69,5300 | -21.306 | -1.481 | 57.027 | ||||
| 2026-05-01 | 2026-05-01 | 4 | Sloan Sheldon | SYRE | Common Stock | D | 27,4600 | 78.333 | 2.151 | 78.333 | ||||
| 2026-04-03 | 2026-04-01 | 4 | Turtle Cameron | SYRE | Common Stock | D | 49,9200 | -2.656 | -133 | 627.540 | ||||
| 2026-04-03 | 2026-04-01 | 4 | Turtle Cameron | SYRE | Common Stock | D | 49,2000 | -12.344 | -607 | 630.196 | ||||
| 2026-04-03 | 2026-04-01 | 4 | Sloan Sheldon | SYRE | Common Stock | D | 50,0000 | -7.958 | -398 | 0 | ||||
| 2026-04-03 | 2026-04-01 | 4 | Sloan Sheldon | SYRE | Common Stock | D | 21,6600 | 7.958 | 172 | 7.958 | ||||
| 2026-04-03 | 2026-04-01 | 4 | Burrows Scott L | SYRE | Common Stock | D | 49,9800 | -1.300 | -65 | 97.994 | ||||
| 2026-04-03 | 2026-04-01 | 4 | Burrows Scott L | SYRE | Common Stock | D | 49,2100 | -6.200 | -305 | 99.294 | ||||
| 2026-04-03 | 2026-04-01 | 4 | Burrows Scott L | SYRE | Common Stock | D | 14,5000 | 7.500 | 109 | 105.494 | ||||
| 2026-03-03 | 2026-03-03 | 4 | Burrows Scott L | SYRE | Common Stock | D | 41,6600 | -200 | -8 | 97.994 | ||||
| 2026-03-03 | 2026-03-03 | 4 | Burrows Scott L | SYRE | Common Stock | D | 40,5600 | -2.300 | -93 | 98.194 | ||||
| 2026-03-03 | 2026-03-03 | 4 | Burrows Scott L | SYRE | Common Stock | D | 14,5000 | 2.500 | 36 | 100.494 | ||||
| 2026-03-03 | 2026-03-02 | 4 | Turtle Cameron | SYRE | Common Stock | D | 42,4900 | -9.100 | -387 | 642.540 | ||||
| 2026-03-03 | 2026-03-02 | 4 | Turtle Cameron | SYRE | Common Stock | D | 41,7300 | -5.900 | -246 | 651.640 | ||||
| 2026-02-04 | 2026-02-02 | 4 | Turtle Cameron | SYRE | Common Stock | D | 32,8700 | -14.043 | -462 | 657.540 | ||||
| 2026-02-04 | 2026-02-02 | 4 | Turtle Cameron | SYRE | Common Stock | D | 31,8200 | -957 | -30 | 671.583 | ||||
| 2026-01-23 | 2026-01-21 | 4 | HENDERSON MICHAEL THOMAS | SYRE | Common Stock | D | 63.227 | 168.606 | ||||||
| 2026-01-06 | 2026-01-02 | 4 | Turtle Cameron | SYRE | Common Stock | D | 32,3900 | -100 | -3 | 671.907 | ||||
| 2026-01-06 | 2026-01-02 | 4 | Turtle Cameron | SYRE | Common Stock | D | 31,7900 | -2.191 | -70 | 672.007 | ||||
| 2026-01-06 | 2026-01-02 | 4 | Turtle Cameron | SYRE | Common Stock | D | 30,4700 | -12.709 | -387 | 674.198 | ||||
| 2025-12-03 | 2025-12-01 | 4 | Turtle Cameron | SYRE | Common Stock | D | 29,8300 | -4.005 | -119 | 686.907 | ||||
| 2025-12-03 | 2025-12-01 | 4 | Turtle Cameron | SYRE | Common Stock | D | 28,7300 | -10.995 | -316 | 690.912 | ||||
| 2025-11-05 | 2025-11-03 | 4 | Turtle Cameron | SYRE | Common Stock | D | 23,6600 | -16.845 | -399 | 701.907 | ||||
| 2025-11-05 | 2025-11-03 | 4 | Turtle Cameron | SYRE | Common Stock | D | 23,1300 | -28.155 | -651 | 718.752 | ||||
| 2025-09-03 | 2025-09-02 | 4 | Burrows Scott L | SYRE | Common Stock | D | 16,2600 | -18.428 | -300 | 97.994 | ||||
| 2025-01-14 | 2025-01-10 | 4 | HENDERSON MICHAEL THOMAS | SYRE | Common Stock | D | 105.379 | 105.379 | ||||||
| 2024-11-08 | 2024-11-06 | 4 | Albers Jeffrey W. By Sessions LLC | SYRE | Common Stock | I | 36,7631 | -6.700 | -246 | 27.360 | ||||
| 2024-10-28 | 2024-10-25 | 4 | Albers Jeffrey W. By Sessions LLC | SYRE | Common Stock | I | 36,4300 | -300 | -11 | 34.060 | ||||
| 2024-09-05 | 2024-09-03 | 4 | Burrows Scott L | SYRE | Common Stock | D | 28,1730 | -18.531 | -522 | 116.422 | ||||
| 2024-04-25 | 2024-04-25 | 4 | Fairmount Funds Management LLC By Fairmount Healthcare Fund II L.P. | SYRE | Common Stock | I | 3.639.680 | 4.018.101 | ||||||
| 2024-02-20 | 2024-02-15 | 4 | Turtle Cameron | SYRE | Common Stock | D | 9,8200 | 400 | 4 | 746.907 | ||||
| 2023-12-29 | 2023-12-29 | 4 | Fairmount Funds Management LLC By Peter Harwin | SYRE | Common Stock | I | 406.038 | 406.038 | ||||||
| 2023-12-29 | 2023-12-29 | 4 | Fairmount Funds Management LLC By Tomas Kiselak | SYRE | Common Stock | I | 406.038 | 406.038 | ||||||
| 2023-12-29 | 2023-12-29 | 4 | Fairmount Funds Management LLC By Fairmount Healthcare Co-Invest L.P. | SYRE | Common Stock | I | -3.435.480 | 0 | ||||||
| 2023-12-22 | 2023-12-22 | 4 | Burrows Scott L | SYRE | Common Stock | D | 134.953 | 134.953 | ||||||
| 2023-12-08 | 2023-11-24 | 4/A | Albers Jeffrey W. By Sessions LLC | SYRE | Common Stock | I | 34.360 | 34.360 | ||||||
| 2023-11-28 | 2023-11-24 | 4 | Fairmount Funds Management LLC By Fairmount Healthcare Co-Invest L.P. | AGLE | Common Stock | I | 3.435.480 | 3.435.480 | ||||||
| 2023-11-27 | 2023-11-24 | 4 | Turtle Cameron | AGLE | Common Stock | D | 723.440 | 746.507 | ||||||
| 2023-06-30 | 3 | Turtle Cameron | AGLE | Common Stock | D | 576.699 | ||||||||
| 2023-06-30 | 3 | Fairmount Funds Management LLC By Fairmount Healthcare Fund LP( | AGLE | Common Stock | I | 276.082 | ||||||||
| 2023-06-30 | 3 | Fairmount Funds Management LLC By Fairmount Healthcare Fund II LP | AGLE | Common Stock | I | 9.184.458 | ||||||||
| 2023-01-27 | 3 | Neuman Linda L | AGLE | Common Stock | D | 4.000 | ||||||||
| 2022-08-25 | 3 | Kastenmayer James Paul | AGLE | Common Stock | D | 4.000 | ||||||||
| 2022-08-25 | 2022-08-25 | 4 | Souza Marcio | AGLE | Common Stock | D | 0,5608 | 90.000 | 50 | 90.000 | ||||
| 2022-06-10 | 2022-06-08 | 4 | Hanley Jr. Michael Conick | AGLE | Common Stock | D | 0,7100 | 28.200 | 20 | 36.200 | ||||
| 2022-03-18 | 2022-03-16 | 4 | Quinn Anthony | AGLE | Common Stock | D | 2,3440 | 80.079 | 188 | 550.540 | ||||
| 2022-03-15 | 2022-03-15 | 4 | Quinn Anthony | AGLE | Common Stock | D | 1,8611 | 42.417 | 79 | 473.461 | ||||
| 2022-03-15 | 2022-03-14 | 4 | Quinn Anthony | AGLE | Common Stock | D | 1,9300 | 67.472 | 130 | 431.044 | ||||
| 2022-03-15 | 2022-03-11 | 4 | Quinn Anthony | AGLE | Common Stock | D | 2,0640 | 34.777 | 72 | 363.572 | ||||
| 2022-03-15 | 2022-03-11 | 4 | Alspaugh Jonathan | AGLE | Common Stock | D | 2,0800 | 75.000 | 156 | 165.372 | ||||
| 2022-02-22 | 2022-02-17 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 3,17 | 350.000 | 350.000 | |||||
| 2022-02-22 | 2022-02-17 | 4 | Weber Steven | AGLE | Employee Stock Option (right to buy) | D | 3,17 | 30.000 | 30.000 | |||||
| 2022-02-22 | 2022-02-17 | 4 | Sloan Leslie | AGLE | Employee Stock Option (right to buy) | D | 3,17 | 180.000 | 180.000 | |||||
| 2022-02-22 | 2022-02-17 | 4 | Hanley Jr. Michael Conick | AGLE | Employee Stock Option (right to buy) | D | 3,17 | 160.000 | 160.000 | |||||
| 2022-02-22 | 2022-02-17 | 4 | Alspaugh Jonathan | AGLE | Employee Stock Option (right to buy) | D | 3,17 | 170.000 | 170.000 | |||||
| 2022-02-14 | 2021-10-20 | 5 | Quinn Anthony | AGLE | Common Stock | I | 10.000 | 208.845 | ||||||
| 2022-02-14 | 2021-10-20 | 5 | Quinn Anthony | AGLE | Common Stock | D | -10.000 | 328.795 | ||||||
| 2022-02-14 | 2021-10-18 | 5 | Quinn Anthony | AGLE | Common Stock | I | 23.809 | 208.845 | ||||||
| 2022-02-14 | 2021-10-18 | 5 | Quinn Anthony | AGLE | Common Stock | D | -23.809 | 328.795 | ||||||
| 2022-02-14 | 2021-10-14 | 5 | Quinn Anthony | AGLE | Common Stock | I | 175.036 | 208.845 | ||||||
| 2022-02-14 | 2021-10-14 | 5 | Quinn Anthony | AGLE | Common Stock | D | -175.036 | 328.795 | ||||||
| 2022-02-14 | 2018-12-28 | 5 | Quinn Anthony | AGLE | Common Stock | I | 57.450 | 57.450 | ||||||
| 2022-02-14 | 2018-12-28 | 5 | Quinn Anthony | AGLE | Common Stock | D | -57.450 | 328.795 | ||||||
| 2021-12-13 | 2021-12-13 | 4 | Shanafelt Armen | AGLE | Common Stock | D | 3,6500 | 14.685 | 54 | 150.000 | ||||
| 2021-12-13 | 2021-12-10 | 4 | Shanafelt Armen | AGLE | Common Stock | D | 3,6500 | 13.516 | 49 | 135.315 | ||||
| 2021-12-13 | 2021-12-09 | 4 | Shanafelt Armen | AGLE | Common Stock | D | 3,6680 | 121.799 | 447 | 121.799 | ||||
| 2021-12-13 | 2021-12-10 | 4 | Quinn Anthony | AGLE | Common Stock | D | 3,7500 | 10.526 | 39 | 328.795 | ||||
| 2021-12-13 | 2021-12-09 | 4 | Quinn Anthony | AGLE | Common Stock | D | 3,7000 | 43.108 | 159 | 318.269 | ||||
| 2021-12-13 | 2021-12-09 | 4 | Alspaugh Jonathan | AGLE | Common Stock | D | 3,7200 | 50.000 | 186 | 90.372 | ||||
| 2021-11-16 | 2021-11-12 | 4 | Smith Hunter C | AGLE | Director Stock Option (right to buy) | D | 7,04 | 60.000 | 60.000 | |||||
| 2021-08-18 | 2021-08-18 | 4 | Alspaugh Jonathan | AGLE | Common Stock | D | 6,7222 | 7.200 | 48 | 40.372 | ||||
| 2021-08-18 | 2021-08-17 | 4 | Alspaugh Jonathan | AGLE | Common Stock | D | 6,4973 | 23.392 | 152 | 33.172 | ||||
| 2021-08-18 | 2021-08-16 | 4 | Alspaugh Jonathan | AGLE | Common Stock | D | 6,3676 | 9.780 | 62 | 9.780 | ||||
| 2021-07-08 | 2021-07-06 | 4 | Alspaugh Jonathan | AGLE | Employee Stock Option (right to buy) | D | 7,03 | 160.000 | 160.000 | |||||
| 2021-06-22 | 2021-06-18 | 4 | Souza Marcio | AGLE | Director Stock Option (right to buy) | D | 6,44 | 60.000 | 60.000 | |||||
| 2021-06-10 | 2021-06-08 | 4 | BAKER BROS. ADVISORS LP See Footnotes | AGLE | Non-Qualified Stock Option (right to buy) | I | 6,80 | 40.000 | 40.000 | |||||
| 2021-06-09 | 2021-06-08 | 4 | Mahatme Sandesh | AGLE | Director Stock Option (right to buy) | D | 6,80 | 40.000 | 40.000 | |||||
| 2021-06-09 | 2021-06-08 | 4 | Shanafelt Armen | AGLE | Director Stock Option (right to buy) | D | 6,80 | 40.000 | 40.000 | |||||
| 2021-06-09 | 2021-06-08 | 4 | Magovcevic Ivana | AGLE | Director Stock Option (right to buy) | D | 6,80 | 40.000 | 40.000 | |||||
| 2021-06-09 | 2021-06-08 | 4 | LAWLIS V BRYAN | AGLE | Director Stock Option (right to buy) | D | 6,80 | 40.000 | 40.000 | |||||
| 2021-06-09 | 2021-06-08 | 4 | Lawton Alison Frances | AGLE | Director Stock Option (right to buy) | D | 6,80 | 40.000 | 40.000 | |||||
| 2021-06-09 | 2021-06-08 | 4 | Cox Russell J. | AGLE | Director Stock Option (right to buy) | D | 6,80 | 40.000 | 40.000 | |||||
| 2021-02-25 | 3 | BAKER JULIAN See Footnotes | AGLE | Common Stock | I | 3.094.590 | ||||||||
| 2021-02-25 | 3 | BAKER JULIAN See Footnotes | AGLE | Common Stock | I | 315.516 | ||||||||
| 2021-02-25 | 2021-02-23 | 4 | BAKER BROS. ADVISORS LP See Footnotes | AGLE | Non-Qualified Stock Option (right to buy) | I | 7,11 | 47.200 | 47.200 | |||||
| 2021-02-19 | 2021-02-17 | 4 | Weber Steven | AGLE | Employee Stock Option (right to buy) | D | 7,35 | 50.000 | 50.000 | |||||
| 2021-02-19 | 2021-02-17 | 4 | Sloan Leslie | AGLE | Employee Stock Option (right to buy) | D | 7,35 | 160.000 | 160.000 | |||||
| 2021-02-19 | 2021-02-17 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 7,35 | 330.000 | 330.000 | |||||
| 2021-02-19 | 2021-02-17 | 4 | Hanley Jr. Michael Conick | AGLE | Employee Stock Option (right to buy) | D | 7,35 | 135.000 | 135.000 | |||||
| 2021-02-08 | 3 | Weber Steven | AGLE | Common Stock | D | 17.652 | ||||||||
| 2020-12-17 | 2020-12-15 | 4 | Lawton Alison Frances | AGLE | Director Stock Option (right to buy) | D | 9,09 | 47.200 | 47.200 | |||||
| 2020-06-10 | 2020-06-08 | 4 | Shanafelt Armen | AGLE | Director Stock Option (right to buy) | D | 8,89 | 28.100 | 28.100 | |||||
| 2020-06-10 | 2020-06-08 | 4 | Bruhn Suzanne Louise | AGLE | Director Stock Option (right to buy) | D | 8,89 | 28.100 | 28.100 | |||||
| 2020-06-10 | 2020-06-08 | 4 | Cox Russell J. | AGLE | Director Stock Option (right to buy) | D | 8,89 | 28.100 | 28.100 | |||||
| 2020-06-10 | 2020-06-08 | 4 | LAWLIS V BRYAN | AGLE | Director Stock Option (right to buy) | D | 8,89 | 28.100 | 28.100 | |||||
| 2020-06-10 | 2020-06-08 | 4 | Magovcevic Ivana | AGLE | Director Stock Option (right to buy) | D | 8,89 | 28.100 | 28.100 | |||||
| 2020-06-10 | 2020-06-08 | 4 | Mahatme Sandesh | AGLE | Director Stock Option (right to buy) | D | 8,89 | 28.100 | 28.100 | |||||
| 2020-05-04 | 2020-04-30 | 4 | Quinn Anthony | AGLE | Common Stock | D | 4,7500 | 165.000 | 784 | 538.469 | ||||
| 2020-02-19 | 2020-02-14 | 4 | Rao Madduri Ravin | AGLE | Employee Stock Option (right to buy) | D | 8,15 | 25.000 | 25.000 | |||||
| 2020-02-19 | 2020-02-14 | 4 | Sloan Leslie | AGLE | Employee Stock Option (right to buy) | D | 8,15 | 100.000 | 100.000 | |||||
| 2020-02-19 | 2020-02-14 | 4 | York Charles N II | AGLE | Employee Stock Option (right to buy) | D | 8,15 | 126.000 | 126.000 | |||||
| 2020-02-19 | 2020-02-14 | 4 | Hanley Jr. Michael Conick | AGLE | Employee Stock Option (right to buy) | D | 8,15 | 25.000 | 25.000 | |||||
| 2020-02-19 | 2020-02-14 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 8,15 | 301.000 | 301.000 | |||||
| 2019-11-04 | 2019-11-01 | 4 | Rao Madduri Ravin | AGLE | Employee Stock Option (right to buy) | D | 8,24 | 130.000 | 130.000 | |||||
| 2019-10-23 | 2019-10-21 | 4 | Hanley Jr. Michael Conick | AGLE | Employee Stock Option (right to buy) | D | 7,79 | 130.000 | 130.000 | |||||
| 2019-10-07 | 2019-10-04 | 4 | Quinn Anthony | AGLE | Stock Option (right to buy) | D | 6,31 | -17.603 | 119.914 | |||||
| 2019-10-07 | 2019-10-04 | 4 | Quinn Anthony | AGLE | Stock Option (right to buy) | D | 5,46 | -662 | 0 | |||||
| 2019-10-07 | 2019-10-04 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,3100 | 17.603 | 111 | 371.908 | ||||
| 2019-10-07 | 2019-10-04 | 4 | Quinn Anthony | AGLE | Common Stock | D | 5,4600 | 662 | 4 | 354.305 | ||||
| 2019-06-14 | 2019-06-14 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,2311 | 5.282 | 33 | 353.643 | ||||
| 2019-06-14 | 2019-06-13 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,1666 | 14.406 | 89 | 348.361 | ||||
| 2019-06-14 | 2019-06-12 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,1148 | 12.217 | 75 | 333.955 | ||||
| 2019-06-07 | 2019-06-07 | 4 | Bruhn Suzanne Louise | AGLE | Director Stock Option (right to buy) | D | 6,33 | 12.400 | 12.400 | |||||
| 2019-06-07 | 2019-06-07 | 4 | Cox Russell J. | AGLE | Director Stock Option (right to buy) | D | 6,33 | 12.400 | 12.400 | |||||
| 2019-06-07 | 2019-06-07 | 4 | Magovcevic Ivana | AGLE | Director Stock Option (right to buy) | D | 6,33 | 12.400 | 12.400 | |||||
| 2019-06-07 | 2019-06-07 | 4 | Mahatme Sandesh | AGLE | Director Stock Option (right to buy) | D | 6,33 | 12.400 | 12.400 | |||||
| 2019-06-07 | 2019-06-07 | 4 | Shanafelt Armen | AGLE | Director Stock Option (right to buy) | D | 6,33 | 12.400 | 12.400 | |||||
| 2019-06-07 | 2019-06-07 | 4 | LAWLIS V BRYAN | AGLE | Director Stock Option (right to buy) | D | 6,33 | 12.400 | 12.400 | |||||
| 2019-05-22 | 2019-05-22 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,8596 | 3.809 | 26 | 321.738 | ||||
| 2019-05-22 | 2019-05-21 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,8857 | 13.794 | 95 | 317.929 | ||||
| 2019-05-22 | 2019-05-20 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,5550 | 8.989 | 59 | 304.135 | ||||
| 2019-05-17 | 2019-05-17 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,6477 | 6.218 | 41 | 295.146 | ||||
| 2019-05-17 | 2019-05-16 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,8280 | 5.520 | 38 | 288.928 | ||||
| 2019-05-17 | 2019-05-15 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,7566 | 6.256 | 42 | 283.408 | ||||
| 2019-05-17 | 2019-02-15 | 4 | Quinn Anthony | AGLE | Common Stock | D | 7,0980 | 719 | 5 | 277.152 | ||||
| 2019-03-08 | 2019-03-06 | 4 | Sloan Leslie | AGLE | Employee Stock Option (right to buy) | D | 8,06 | 36.000 | 36.000 | |||||
| 2019-03-01 | 2019-02-28 | 4 | Quinn Anthony | AGLE | Stock Option (right to buy) | D | 8,36 | 280.000 | 280.000 | |||||
| 2019-03-01 | 2019-02-28 | 4 | Schuchart Aaron | AGLE | Employee Stock Option (right to buy) | D | 8,36 | 60.000 | 60.000 | |||||
| 2019-03-01 | 2019-02-28 | 4 | Wooldridge James | AGLE | Employee Stock Option (right to buy) | D | 8,36 | 50.200 | 50.200 | |||||
| 2019-03-01 | 2019-02-28 | 4 | York Charles N II | AGLE | Employee Stock Option (right to buy) | D | 8,36 | 87.600 | 87.600 | |||||
| 2019-02-08 | 2019-02-06 | 4 | Quinn Anthony | AGLE | Stock Option (right to buy) | D | 6,31 | -7.433 | 137.517 | |||||
| 2019-02-08 | 2019-02-06 | 4 | Quinn Anthony | AGLE | Stock Option (right to buy) | D | 5,46 | -1.323 | 662 | |||||
| 2019-02-08 | 2019-02-06 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,3100 | 7.433 | 47 | 276.433 | ||||
| 2019-02-08 | 2019-02-06 | 4 | Quinn Anthony | AGLE | Common Stock | D | 5,4600 | 1.323 | 7 | 269.000 | ||||
| 2018-12-10 | 2018-12-07 | 4 | Quinn Anthony | AGLE | Director Stock Option (right to buy) | D | 6,31 | -18.584 | 144.950 | |||||
| 2018-12-10 | 2018-12-07 | 4 | Quinn Anthony | AGLE | Director Stock Option (right to buy) | D | 5,46 | -3.306 | 1.985 | |||||
| 2018-12-10 | 2018-12-07 | 4 | Quinn Anthony | AGLE | Director Stock Option (right to buy) | D | 4,11 | -150.000 | 0 | |||||
| 2018-12-10 | 2018-12-07 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,3100 | 18.584 | 117 | 267.677 | ||||
| 2018-12-10 | 2018-12-07 | 4 | Quinn Anthony | AGLE | Common Stock | D | 5,4600 | 3.306 | 18 | 249.093 | ||||
| 2018-12-10 | 2018-12-07 | 4 | Quinn Anthony | AGLE | Common Stock | D | 4,1100 | 150.000 | 616 | 245.787 | ||||
| 2018-12-10 | 2018-08-15 | 4 | Quinn Anthony | AGLE | Common Stock | D | 9,1300 | 994 | 9 | 95.787 | ||||
| 2018-12-10 | 2018-02-15 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,0200 | 2.000 | 12 | 94.793 | ||||
| 2018-09-28 | 2018-09-27 | 4 | Schuchart Aaron | AGLE | Common Stock | D | 9,5000 | -5.900 | -56 | 2.500 | ||||
| 2018-09-28 | 2018-09-27 | 4 | Schuchart Aaron | AGLE | Common Stock | D | 9,5500 | -100 | -1 | 8.400 | ||||
| 2018-08-21 | 2018-08-17 | 4 | Schuchart Aaron | AGLE | Employee Stock Option (right to buy) | D | 3,50 | -8.500 | 91.500 | |||||
| 2018-08-21 | 2018-08-17 | 4 | Schuchart Aaron | AGLE | Common Stock | D | 3,5000 | 8.500 | 30 | 8.500 | ||||
| 2018-08-15 | 2018-08-13 | 4 | GEORGIOU GEORGE | AGLE | Director Stock Option (right to buy) | D | 4,73 | -20.000 | 10.000 | |||||
| 2018-08-15 | 2018-08-13 | 4 | GEORGIOU GEORGE | AGLE | Director Stock Option (right to buy) | D | 7,28 | -17.333 | 6.667 | |||||
| 2018-08-15 | 2018-08-13 | 4 | GEORGIOU GEORGE | AGLE | Common Stock | D | 4,7300 | 20.000 | 95 | 175.861 | ||||
| 2018-08-15 | 2018-08-13 | 4 | GEORGIOU GEORGE | AGLE | Common Stock | D | 7,2800 | 17.333 | 126 | 155.861 | ||||
| 2018-07-20 | 2018-07-18 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 9,36 | 50.000 | 50.000 | |||||
| 2018-07-20 | 2018-07-18 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 9,36 | 75.000 | 75.000 | |||||
| 2018-07-20 | 2018-07-18 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 9,36 | 75.000 | 75.000 | |||||
| 2018-07-20 | 2018-07-18 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 9,36 | 300.000 | 300.000 | |||||
| 2018-07-17 | 2018-07-13 | 4 | LAWLIS V BRYAN | AGLE | Director Stock Option (right to buy) | D | 8,78 | 36.800 | 36.800 | |||||
| 2018-07-16 | 2018-07-12 | 4 | Quinn Anthony | AGLE | Director Stock Option (right to buy) | D | 6,31 | -14.866 | 163.534 | |||||
| 2018-07-16 | 2018-07-12 | 4 | Quinn Anthony | AGLE | Director Stock Option (right to buy) | D | 7,04 | -24.000 | 0 | |||||
| 2018-07-16 | 2018-07-12 | 4 | Quinn Anthony | AGLE | Common Stock | D | 6,3100 | 14.866 | 94 | 92.793 | ||||
| 2018-07-16 | 2018-07-12 | 4 | Quinn Anthony | AGLE | Common Stock | D | 7,0400 | 24.000 | 169 | 77.927 | ||||
| 2018-07-13 | 2018-07-11 | 4 | Quinn Anthony | AGLE | Director Stock Option (right to buy) | D | 5,46 | -3.307 | 5.291 | |||||
| 2018-07-13 | 2018-07-11 | 4 | Quinn Anthony | AGLE | Common Stock | D | 5,4600 | 3.307 | 18 | 53.927 | ||||
| 2018-06-08 | 2018-06-07 | 4 | Bruhn Suzanne Louise | AGLE | Director Stock Option (right to buy) | D | 10,28 | 18.400 | 18.400 | |||||
| 2018-06-08 | 2018-06-07 | 4 | Cox Russell J. | AGLE | Director Stock Option (right to buy) | D | 10,28 | 18.400 | 18.400 | |||||
| 2018-06-08 | 2018-06-07 | 4 | GEORGIOU GEORGE | AGLE | Director Stock Option (right to buy) | D | 10,28 | 18.400 | 18.400 | |||||
| 2018-06-08 | 2018-06-07 | 4 | Mahatme Sandesh | AGLE | Director Stock Option (right to buy) | D | 10,28 | 18.400 | 18.400 | |||||
| 2018-06-08 | 2018-06-07 | 4 | Shanafelt Armen | AGLE | Director Stock Option (right to buy) | D | 10,28 | 18.400 | 18.400 | |||||
| 2018-05-14 | 2018-05-11 | 4 | Novartis Bioventures Ltd | AGLE | Common Stock | D | 10,0600 | -19.550 | -197 | 2.175.314 | ||||
| 2018-05-11 | 2018-05-10 | 4 | Novartis Bioventures Ltd | AGLE | Common Stock | D | 10,1300 | -22.725 | -230 | 2.194.864 | ||||
| 2018-05-11 | 2018-05-09 | 4 | Novartis Bioventures Ltd | AGLE | Common Stock | D | 10,1100 | -51.230 | -518 | 2.217.589 | ||||
| 2018-05-09 | 2018-05-08 | 4 | Novartis Bioventures Ltd | AGLE | Common Stock | D | 10,0300 | -26.557 | -266 | 2.268.819 | ||||
| 2018-05-09 | 2018-05-07 | 4 | Novartis Bioventures Ltd | AGLE | Common Stock | D | 10,1100 | -15.548 | -157 | 2.295.376 | ||||
| 2018-03-26 | 2018-03-22 | 4 | Magovcevic Ivana | AGLE | Director Stock Option (right to buy) | D | 10,50 | 36.800 | 36.800 | |||||
| 2018-02-22 | 2018-02-20 | 4 | Schuchart Aaron | AGLE | Employee Stock Option (right to buy) | D | 6,31 | 20.000 | 20.000 | |||||
| 2018-02-22 | 2018-02-20 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 6,31 | 178.400 | 178.400 | |||||
| 2018-02-22 | 2018-02-20 | 4 | York Charles N II | AGLE | Employee Stock Option (right to buy) | D | 6,31 | 92.100 | 92.100 | |||||
| 2018-02-22 | 2018-02-20 | 4 | Wooldridge James | AGLE | Employee Stock Option (right to buy) | D | 6,31 | 45.000 | 45.000 | |||||
| 2018-02-20 | 2018-02-15 | 4 | Quinn Anthony | AGLE | Director Stock Option (right to buy) | D | 5,46 | -15.211 | 8.598 | |||||
| 2018-02-20 | 2018-02-15 | 4 | Quinn Anthony | AGLE | Common Stock | D | 5,4600 | 15.211 | 83 | 50.620 | ||||
| 2017-12-08 | 2017-12-08 | 4 | Quinn Anthony | AGLE | Common Stock | D | 5,0650 | 600 | 3 | 35.409 | ||||
| 2017-12-08 | 2017-12-07 | 4 | Quinn Anthony | AGLE | Common Stock | D | 4,9882 | 2.800 | 14 | 34.809 | ||||
| 2017-12-08 | 2017-12-06 | 4 | Quinn Anthony | AGLE | Common Stock | D | 4,9248 | 4.888 | 24 | 32.009 | ||||
| 2017-12-05 | 2017-12-01 | 4 | Cox Russell J. | AGLE | Director Stock Option (right to buy) | D | 4,73 | 30.000 | 30.000 | |||||
| 2017-12-05 | 2017-12-01 | 4 | GEORGIOU GEORGE | AGLE | Director Stock Option (right to buy) | D | 4,73 | 30.000 | 30.000 | |||||
| 2017-12-05 | 2017-12-01 | 4 | Mahatme Sandesh | AGLE | Director Stock Option (right to buy) | D | 4,73 | 30.000 | 30.000 | |||||
| 2017-12-05 | 2017-12-05 | 4 | Quinn Anthony | AGLE | Common Stock | D | 4,9310 | 5.065 | 25 | 27.121 | ||||
| 2017-12-05 | 2017-12-04 | 4 | Quinn Anthony | AGLE | Common Stock | D | 4,9804 | 7.956 | 40 | 22.056 | ||||
| 2017-12-05 | 2017-12-01 | 4 | Quinn Anthony | AGLE | Common Stock | D | 4,5312 | 4.100 | 19 | 14.100 | ||||
| 2017-12-05 | 2017-12-01 | 4 | Shanafelt Armen | AGLE | Director Stock Option (right to buy) | D | 4,73 | 30.000 | 30.000 | |||||
| 2017-12-05 | 2017-12-05 | 4 | York Charles N II | AGLE | Common Stock | D | 4,7554 | 10.241 | 49 | 34.787 | ||||
| 2017-12-05 | 2017-12-04 | 4 | York Charles N II | AGLE | Common Stock | D | 4,9699 | 3.259 | 16 | 24.546 | ||||
| 2017-12-05 | 2017-12-01 | 4 | York Charles N II | AGLE | Common Stock | D | 4,5931 | 6.500 | 30 | 21.287 | ||||
| 2017-12-05 | 2017-08-15 | 4 | York Charles N II | AGLE | Common Stock | D | 2,5160 | 1.959 | 5 | 14.787 | ||||
| 2017-12-05 | 2017-02-15 | 4 | York Charles N II | AGLE | Common Stock | D | 4,2840 | 2.000 | 9 | 12.828 | ||||
| 2017-12-05 | 2016-08-15 | 4 | York Charles N II | AGLE | Common Stock | D | 3,9870 | 2.000 | 8 | 10.828 | ||||
| 2017-09-01 | 2017-08-31 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 4,11 | 150.000 | 150.000 | |||||
| 2017-08-24 | 2017-08-22 | 4 | Rowlinson Scott W | AGLE | Employee Stock Option (right to buy) | D | 3,10 | 25.000 | 25.000 | |||||
| 2017-08-24 | 2017-08-22 | 4 | Schuchart Aaron | AGLE | Employee Stock Option (right to buy) | D | 3,10 | 10.000 | 10.000 | |||||
| 2017-08-24 | 2017-08-22 | 4 | TYLER JOSEPH E | AGLE | Employee Stock Option (right to buy) | D | 3,10 | 25.000 | 25.000 | |||||
| 2017-08-24 | 2017-08-22 | 4 | Wooldridge James | AGLE | Employee Stock Option (right to buy) | D | 3,10 | 10.000 | 10.000 | |||||
| 2017-08-24 | 2017-08-22 | 4 | Wooldridge James | AGLE | Employee Stock Option (right to buy) | D | 3,10 | 165.000 | 165.000 | |||||
| 2017-08-24 | 2017-08-22 | 4 | York Charles N II | AGLE | Employee Stock Option (right to buy) | D | 3,10 | 58.500 | 58.500 | |||||
| 2017-06-20 | 2017-06-16 | 4 | Schuchart Aaron | AGLE | Employee Stock Option (right to buy) | D | 3,50 | 100.000 | 100.000 | |||||
| 2017-04-25 | 2017-04-21 | 4 | Quinn Anthony | AGLE | Employee Stock Option (right to buy) | D | 7,04 | 24.000 | 24.000 | |||||
| 2017-03-22 | 2017-03-20 | 4 | TYLER JOSEPH E | AGLE | Employee Stock Option (right to buy) | D | 8,03 | 39.000 | 39.000 | |||||
| 2017-03-22 | 2017-03-20 | 4 | York Charles N II | AGLE | Employee Stock Option (right to buy) | D | 8,03 | 90.000 | 90.000 | |||||
| 2017-03-22 | 2017-03-20 | 4 | Hebel Henry | AGLE | Employee Stock Option (right to buy) | D | 8,03 | 38.200 | 38.200 | |||||
| 2017-03-22 | 2017-03-20 | 4 | Lowe David George | AGLE | Employee Stock Option (right to buy) | D | 8,03 | 160.000 | 160.000 | |||||
| 2017-03-22 | 2017-03-20 | 4 | Rowlinson Scott W | AGLE | Employee Stock Option (right to buy) | D | 8,03 | 60.000 | 60.000 | |||||
| 2017-02-21 | 2017-02-21 | 4 | ORBIMED ADVISORS LLC See Footnotes | AGLE | Common Stock | I | 5,3600 | 7.000 | 38 | 1.469.524 | ||||
| 2017-02-21 | 2017-02-17 | 4 | ORBIMED ADVISORS LLC See Footnotes | AGLE | Common Stock | I | 5,1900 | 71.800 | 373 | 1.462.524 | ||||
| 2017-02-21 | 2017-02-16 | 4 | ORBIMED ADVISORS LLC See Footnotes | AGLE | Common Stock | I | 5,0400 | 30.500 | 154 | 1.390.724 | ||||
| 2017-02-16 | 2017-02-15 | 4 | Bruhn Suzanne Louise | AGLE | Director Stock Option (right to buy) | D | 5,04 | 82.000 | 82.000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | Cox Russell J. | AGLE | Director Stock Option (right to buy) | D | 7,28 | 10.000 | 10.000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | Lowe David George | AGLE | Employee Stock Option (right to buy) | D | 7,28 | 160.000 | 160.000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | Mahatme Sandesh | AGLE | Director Stock Option (right to buy) | D | 7,28 | 10.000 | 10.000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | TYLER JOSEPH E | AGLE | Employee Stock Option (right to buy) | D | 7,28 | 33.000 | 33.000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | York Charles N II | AGLE | Employee Stock Option (right to buy) | D | 7,28 | 55.000 | 55.000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | Rowlinson Scott W | AGLE | Employee Stock Option (right to buy) | D | 7,28 | 47.000 | 47.000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | Shanafelt Armen | AGLE | Director Stock Option (right to buy) | D | 7,28 | 24.000 | 24.000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | Hebel Henry | AGLE | Employee Stock Option (right to buy) | D | 7,28 | 43.000 | 43.000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | Rojas-Caro Sandra | AGLE | Employee Stock Option | D | 7,28 | 200.000 | 200.000 | |||||
| 2016-05-19 | 2016-05-17 | 4 | GEORGIOU GEORGE | AGLE | Director Stock Option (right to buy) | D | 7,28 | 24.000 | 24.000 | |||||
| 2016-04-19 | 3 | ISALY SAMUEL D | AGLE | Common Stock | I | 2.720.448 | ||||||||
| 2016-04-19 | 3 | ISALY SAMUEL D | AGLE | Common Stock | I | 2.720.448 | ||||||||
| 2016-04-19 | 3 | ISALY SAMUEL D | AGLE | Common Stock | I | 2.720.448 | ||||||||
| 2016-04-19 | 3 | ISALY SAMUEL D | AGLE | Common Stock | I | 2.720.448 | ||||||||
| 2016-04-14 | 3/A | Shanafelt Armen by fund | AGLE | Common Stock | I | 57.619 | ||||||||
| 2016-04-14 | 2016-04-12 | 4/A | LILLY ELI & CO by fund | AGLE | Common Stock | I | 2.010.924 | 2.068.543 | ||||||
| 2016-04-14 | 2016-04-12 | 4 | LILLY ELI & CO by fund | AGLE | Series B Preferred Stock | I | 0,00 | -1.120.448 | 0 | |||||
| 2016-04-14 | 2016-04-12 | 4 | LILLY ELI & CO by fund | AGLE | Series A Preferred Stock | I | 0,00 | -890.476 | 0 | |||||
| 2016-04-14 | 2016-04-12 | 4 | LILLY ELI & CO by fund | AGLE | Common Stock | I | 10,0000 | 500.000 | 5.000 | 2.568.543 | ||||
| 2016-04-14 | 2016-04-12 | 4 | LILLY ELI & CO by fund | AGLE | Common Stock | I | 2.010.924 | 2.068.543 | ||||||
| 2016-04-12 | 2016-04-12 | 4 | Cox Russell J. | AGLE | Common Stock | D | 10,0000 | 7.000 | 70 | 7.000 | ||||
| 2016-04-12 | 2016-04-12 | 4 | Lowe David George By trust | AGLE | Series B Preferred Stock | I | 0,00 | -2.801 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | Lowe David George By trust | AGLE | Series A Preferred Stock | I | 0,00 | -2.857 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | Lowe David George By trust | AGLE | Common Stock | I | 5.658 | 5.658 | ||||||
| 2016-04-12 | 2016-04-12 | 4 | Novartis Bioventures Ltd | AGLE | Series B Preferred Stock | D | 0,00 | -1.120.448 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | Novartis Bioventures Ltd | AGLE | Series A Preferred Stock | D | 0,00 | -890.476 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | Novartis Bioventures Ltd | AGLE | Common Stock | D | 10,0000 | 300.000 | 3.000 | 2.310.924 | ||||
| 2016-04-12 | 2016-04-12 | 4 | Novartis Bioventures Ltd | AGLE | Common Stock | D | 2.010.924 | 2.010.924 | ||||||
| 2016-04-12 | 2016-04-12 | 4 | Quinn Anthony | AGLE | Common Stock | D | 10,0000 | 10.000 | 100 | 10.000 | ||||
| 2016-04-12 | 2016-04-12 | 4 | TYLER JOSEPH E | AGLE | Series B Preferred Stock | D | 0,00 | -8.403 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | TYLER JOSEPH E | AGLE | Series A Preferred Stock | D | 0,00 | -22.857 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | TYLER JOSEPH E | AGLE | Common Stock | D | 31.260 | 42.428 | ||||||
| 2016-04-12 | 2016-04-12 | 4 | York Charles N II By IRA | AGLE | Series B Preferred Stock | I | 0,00 | -2.037 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | York Charles N II By IRA | AGLE | Series A Preferred Stock | I | 0,00 | -9.523 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | York Charles N II | AGLE | Series B Preferred Stock | D | 0,00 | -1.324 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | York Charles N II By IRA | AGLE | Common Stock | I | 11.560 | 11.560 | ||||||
| 2016-04-12 | 2016-04-12 | 4 | York Charles N II | AGLE | Common Stock | D | 1.324 | 8.828 | ||||||
| 2016-04-12 | 2016-04-12 | 4 | Rowlinson Scott W By trust | AGLE | Series B Preferred Stock | I | 0,00 | -11.204 | 0 | |||||
| 2016-04-12 | 2016-04-12 | 4 | Rowlinson Scott W By trust | AGLE | Common Stock | I | 11.204 | 11.204 | ||||||
| 2016-04-06 | 3 | Shanafelt Armen By fund | AGLE | Common Stock | I | 115.238 | ||||||||
| 2016-04-06 | 3 | Shanafelt Armen By fund | AGLE | Common Stock | I | 115.238 | ||||||||
| 2016-04-06 | 3 | Rowlinson Scott W | AGLE | Common Stock | D | 33.498 | ||||||||
| 2016-04-06 | 3 | Rowlinson Scott W | AGLE | Common Stock | D | 33.498 | ||||||||
| 2016-04-06 | 3 | TYLER JOSEPH E | AGLE | Common Stock | D | 22.336 | ||||||||
| 2016-04-06 | 3 | TYLER JOSEPH E | AGLE | Common Stock | D | 22.336 | ||||||||
| 2016-04-06 | 3 | GEORGIOU GEORGE Held by GMA Technologies L.L.C. | AGLE | Common Stock | I | 574.004 | ||||||||
| 2016-04-06 | 3 | GEORGIOU GEORGE | AGLE | Common Stock | D | 547.532 | ||||||||
| 2016-04-06 | 3 | GEORGIOU GEORGE By trust | AGLE | Common Stock | I | 514.480 | ||||||||
| 2016-04-06 | 3 | GEORGIOU GEORGE Held by GMA Technologies L.L.C. | AGLE | Common Stock | I | 574.004 | ||||||||
| 2016-04-06 | 3 | GEORGIOU GEORGE | AGLE | Common Stock | D | 547.532 | ||||||||
| 2016-04-06 | 3 | GEORGIOU GEORGE By trust | AGLE | Common Stock | I | 514.480 | ||||||||
| 2016-04-06 | 3 | Lowe David George | AGLE | Common Stock | D | 412.764 | ||||||||
| 2016-04-06 | 3 | Lowe David George | AGLE | Common Stock | D | 412.764 | ||||||||
| 2016-04-06 | 3 | York Charles N II | AGLE | Common Stock | D | 15.008 | ||||||||
| 2016-04-06 | 3 | York Charles N II | AGLE | Common Stock | D | 15.008 | ||||||||
| 2016-04-06 | 3 | Torres S. Edward | AGLE | Common Stock | D | 115.238 | ||||||||
| 2016-04-06 | 3 | Torres S. Edward | AGLE | Common Stock | D | 115.238 | ||||||||
| 2016-04-06 | 3 | Torres S. Edward | AGLE | Common Stock | D | 115.238 | ||||||||
| 2016-04-06 | 3 | Torres S. Edward | AGLE | Common Stock | D | 115.238 |
